The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 04, 2024
Filed:
May. 07, 2019
Applicant:
Syndax Pharmaceuticals, Inc., Waltham, MA (US);
Inventors:
Peter Ordentlich, Lexington, MA (US);
Lei Wang, Waltham, MA (US);
Serap Sankoh, Waltham, MA (US);
Michael Meyers, Waltham, MA (US);
Assignee:
Syndax Pharmaceuticals, Inc., Waltham, MA (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/569 (2006.01); A61K 9/00 (2006.01); A61K 31/4406 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); G01N 33/574 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
G01N 33/56977 (2013.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 31/4406 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); G01N 33/56972 (2013.01); G01N 33/57423 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); G01N 2333/70535 (2013.01); G01N 2333/70539 (2013.01); G01N 2333/70596 (2013.01); G01N 2800/52 (2013.01);
Abstract
Described herein are methods for selecting cancer patients for treatment with a combination therapy comprising an HDAC inhibitor and a second therapeutic agent. In particular, methods are provided for the examination of a non-cancer cell type which are CD14-positive, HLA-DR-high and/or CD16-negative, as a therapeutic indicator in the setting of HDAC inhibitor combination therapies.